Telix Pharmaceuticals’ (TLX) Outperform Rating Reiterated at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating restated by analysts at Wedbush in a research note issued on Wednesday, Benzinga reports. They currently have a $22.00 target price on the stock. Wedbush‘s price target points to a potential upside of 118.80% from the company’s current price.

TLX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Friday, September 25th. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 21st. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $20.50.

Telix Pharmaceuticals Stock Performance

Shares of TLX stock traded down $1.11 during trading hours on Wednesday, hitting $10.06. The company had a trading volume of 232,650 shares, compared to its average volume of 232,394. The company’s fifty day moving average is $11.49 and its 200 day moving average is $10.78. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $13.11.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $1,731,000. Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares during the period. XY Capital Ltd boosted its position in Telix Pharmaceuticals by 468.0% in the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after buying an additional 58,739 shares during the period. Lazard Asset Management LLC boosted its position in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares during the period. Finally, WoodTrust Financial Corp acquired a new position in shares of Telix Pharmaceuticals in the third quarter worth $186,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.